GlycoMira Patents

Patent portfolio assigned to GlycoMira (verified via public assignee records). Estimated patent count: 4. GlycoMira Therapeutics - active clinical-stage biopharma (Salt Lake City, founded 2008); synthetic glycosaminoglycan / glycan therapeutics, lead GM-1111 (FDA IND accepted Feb 2025). Has patents (assignee on Google Patents/Justia; key US Patent 12109225, WO2016122889A1) - several visible, estimate ~4. No named customers (B2B drug developer); funded by NIH (~$2.8M grant) - funder, not customer. No competitors stated on own site.